2
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Percepción y factores asociados a la posibilidad de vacunarse contra Covid-19 en trabajadores de la zona rural de Chupaca-Perú, 2021 Translated title: Perception and factors associated with the possibility of getting vaccines against Covid-19 in workers in the rural zone of Chupaca-Peru, 2021.

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          RESUMEN. Introducción: Se ha determinado la percepción de vacunarse contra la COVID-19 en múltiples poblaciones laborales, pero esto no ha sido medido en población rural, que muchas veces tiene diferencias importantes de la urbana. Objetivo: Determinar los factores sociolaborales asociados a la negativa a la vacunación contra la COVID-19 en trabajadores rurales de la sierra central peruana. Material y Métodos: Estudio transversal analítico, se usó la Escala-VAC-COVID-19 para medir la percepción acerca de la vacunación, esto se cruzó con variables sociolaborales y se obtuvo estadística descriptiva y analítica. Resultados: En el análisis multivariado, los que no querían vacunarse pertenecían al sector agricultura (RPa: 1,88; valor p=0,003), quienes aún no tuvieron la enfermedad (RPa: 1,61; valor p=0,045) o que no sabían si la habían tenido (RPa: 1,85; valor p=0,017). Los que más querían vacunarse eran los del sector salud (RPa: 0,12; valor p=0,031). Conclusión: El mayor porcentaje de negativa a la vacunación estuvo en quienes pertenecían al sector agricultura, quienes aún no tuvieron la enfermedad o que no sabían si la habían tenido, y el mayor porcentaje de aceptación estuvo en el sector salud.

          Translated abstract

          ABSTRACT Introduction: The perception of being vaccinated against COVID-19 has been determined in multiple working populations, but this has not been measured in the rural population, which often has important differences from the urban one. Objective: To determine the sociolaboral factors associated with the refusal of vaccination against COVID-19 in rural workers of the central Peruvian highlands. Material and Methods: Analytical cross-sectional study, the VAC-COVID-19 Scale was used to measure the perception about vaccination, this was crossed with sociolaboral variables and descriptive and analytical statistics were obtained. Results: In the multivariate analysis, those who did not want to be vaccinated belonged to the agricultural sector (PRa: 1.88; p-value=0.003), those who had not yet had the disease (PRa: 1.61; p-value=0.045) or who did not know if they had had it (PRa: 1.85; p-value=0.017). Those who most wanted to be vaccinated were those in the health sector (RPa: 0.12; p-value=0.031). Conclusion: The highest percentage of refusal to vaccination was in those who belonged to the agricultural sector, those who had not yet had the disease or did not know if they had had it, and the highest percentage of acceptance was in the health sector.

          Related collections

          Most cited references26

          • Record: found
          • Abstract: found
          • Article: not found

          Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape

          Where 2020 saw the development and testing of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at an unprecedented pace, the first half of 2021 has seen vaccine rollout in many countries. In this Progress article, we provide a snapshot of ongoing vaccine efficacy studies, as well as real-world data on vaccine effectiveness and the impact of virus variants of concern. Where they have been deployed in a high proportion of the adult population, the currently approved vaccines have been extremely effective in preventing COVID-19, particularly severe disease. Nonetheless, there are still significant challenges in ensuring equitable vaccine access around the globe and lessons that can be learned for controlling this pandemic and for the next pandemic. This Progress article provides an update on the COVID-19 vaccine effort in the light of ongoing vaccine efficacy studies and real-world data on vaccine effectiveness, including the impact of virus variants of concern and challenges for global deployment.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study

            Background BNT162b2 mRNA and ChAdOx1 nCOV-19 adenoviral vector vaccines have been rapidly rolled out in the UK from December, 2020. We aimed to determine the factors associated with vaccine coverage for both vaccines and documented the vaccine effectiveness of the BNT162b2 mRNA vaccine in a cohort of health-care workers undergoing regular asymptomatic testing. Methods The SIREN study is a prospective cohort study among staff (aged ≥18 years) working in publicly-funded hospitals in the UK. Participants were assigned into either the positive cohort (antibody positive or history of infection [indicated by previous positivity of antibody or PCR tests]) or the negative cohort (antibody negative with no previous positive test) at the beginning of the follow-up period. Baseline risk factors were collected at enrolment, symptom status was collected every 2 weeks, and vaccination status was collected through linkage to the National Immunisations Management System and questionnaires. Participants had fortnightly asymptomatic SARS-CoV-2 PCR testing and monthly antibody testing, and all tests (including symptomatic testing) outside SIREN were captured. Data cutoff for this analysis was Feb 5, 2021. The follow-up period was Dec 7, 2020, to Feb 5, 2021. The primary outcomes were vaccinated participants (binary ever vacinated variable; indicated by at least one vaccine dose recorded by at least one of the two vaccination data sources) for the vaccine coverage analysis and SARS-CoV-2 infection confirmed by a PCR test for the vaccine effectiveness analysis. We did a mixed-effect logistic regression analysis to identify factors associated with vaccine coverage. We used a piecewise exponential hazard mixed-effects model (shared frailty-type model) using a Poisson distribution to calculate hazard ratios to compare time-to-infection in unvaccinated and vaccinated participants and estimate the impact of the BNT162b2 vaccine on all PCR-positive infections (asymptomatic and symptomatic). This study is registered with ISRCTN, number ISRCTN11041050, and is ongoing. Findings 23 324 participants from 104 sites (all in England) met the inclusion criteria for this analysis and were enrolled. Included participants had a median age of 46·1 years (IQR 36·0–54·1) and 19 692 (84%) were female; 8203 (35%) were assigned to the positive cohort at the start of the analysis period, and 15 121 (65%) assigned to the negative cohort. Total follow-up time was 2 calendar months and 1 106 905 person-days (396 318 vaccinated and 710 587 unvaccinated). Vaccine coverage was 89% on Feb 5, 2021, 94% of whom had BNT162b2 vaccine. Significantly lower coverage was associated with previous infection, gender, age, ethnicity, job role, and Index of Multiple Deprivation score. During follow-up, there were 977 new infections in the unvaccinated cohort, an incidence density of 14 infections per 10 000 person-days; the vaccinated cohort had 71 new infections 21 days or more after their first dose (incidence density of eight infections per 10 000 person-days) and nine infections 7 days after the second dose (incidence density four infections per 10 000 person-days). In the unvaccinated cohort, 543 (56%) participants had typical COVID-19 symptoms and 140 (14%) were asymptomatic on or 14 days before their PCR positive test date, compared with 29 (36%) with typical COVID-19 symptoms and 15 (19%) asymptomatic in the vaccinated cohort. A single dose of BNT162b2 vaccine showed vaccine effectiveness of 70% (95% CI 55–85) 21 days after first dose and 85% (74–96) 7 days after two doses in the study population. Interpretation Our findings show that the BNT162b2 vaccine can prevent both symptomatic and asymptomatic infection in working-age adults. This cohort was vaccinated when the dominant variant in circulation was B1.1.7 and shows effectiveness against this variant. Funding Public Health England, UK Department of Health and Social Care, and the National Institute for Health Research.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Intention to participate in a COVID-19 vaccine clinical trial and to get vaccinated against COVID-19 in France during the pandemic

              Highlights • Nearly 75 % of the survey respondents indicated that they were likely to accept COVID-19 vaccine. • 48 % of the survey respondents were likely to accept to participate in a vaccine clinical trial if asked against SARS-CoV-2 infections. • Healthcare workers were more prone to get vaccinated against COVID-19 than non HCWs.
                Bookmark

                Author and article information

                Journal
                medtra
                Revista de la Asociación Española de Especialistas en Medicina del Trabajo
                Rev Asoc Esp Espec Med Trab
                Asociación Española de Especialistas en Medicina del Trabajo (Madrid, Madrid, Spain )
                1132-6255
                3020-1160
                2022
                : 31
                : 2
                : 135-145
                Affiliations
                [3] Lima Lima orgnameUniversidad Privada Norbert Wiener orgdiv1Centro de Investigación en Medicina Traslacional Peru
                [1] Huancayo Estado de México orgnameUniversidad Continental Mexico
                [2] orgnameUniversidad Continental, Huancayo Perú
                Article
                S3020-11602022000200002 S3020-1160(22)03100200002
                7ad7041c-41e1-46eb-98b4-a816fe56adf3

                This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

                History
                : 04 July 2022
                : 29 September 2021
                Page count
                Figures: 0, Tables: 0, Equations: 0, References: 26, Pages: 11
                Product

                SciELO Spain

                Categories
                Textos Originales

                COVID-19,Perú,Peru,vacunación,occupational health,salud ocupacional,trabajadores rurales,vaccination,rural workers

                Comments

                Comment on this article